Norway, Oct. 27 -- ArcticZymes Technologies ASA announced the early-access launch of RiboCleanT dsDNase and RiboCleaveT 1, its first enzymes developed specifically for RNA therapeutics manufacturing and analysis. The launch coincides with the opening of the 33rd ESGCT Annual Congress at the Congress Centre Hamburg, Germany (27-30 October 2026).As RNA therapeutics advance toward commercial-scale manufacturing, improving process efficiency, reducing costs and simplifying analytical workflows are becoming increasingly important. ArcticZymes' two new enzymes address these challenges at critical stages of RNA manufacturing and quality analysis.RiboCleanT dsDNase can be integrated directly into existing IVT workflows without additional buffer or ...